Q32 Bio Inc. · NASDAQ:QTTB
Q32 Bio — EADV Congress 2026
16 slides from Q32 Bio's conference presentation, Sep 30, 2026
Slide 1: Bempikibart produces hair regrowth that persists off treatment in alopecia areata
Bempikibart, a novel IL-7Rα antibody, produces hair regrowth that persists off treatment in severe and very severe alopecia areata: efficacy and biomarker results from the Phase 2a SIGNAL-AA Part B trial Arash Mostaghimi1,2, Shelia Violette3, Christine G Lian1,2, Meghanadh Yerram3, Bhavya Haria3, Sa
Slide 2: Disclosures
Disclosures • Presenter disclosures: AM has been a consultant and received honoraria from hims and hers, AbbVie, Sun Pharma, Pfizer, Lilly, Boehringer Ingelheim, Indomo, Olaplex, Legacy Healthcare, and Pelage, Soterios, Matchpoint Therapeutics, Dren Labs, LEO Pharma and Q32 Bio. • Investigational pr
Slide 3: Alopecia Areata and the Rationale for IL-7Rα Blockade with Bempikibart
Alopecia Areata and the Rationale for IL-7Rα Blockade with Bempikibart Alopecia areata • T-cell–mediated autoimmune disease of the hair follicle • Approved oral JAK inhibitors require continuous administration; relapse commonly observed after discontinuation • Unmet need: Safe, convenient therapeuti
Slide 4: SIGNAL-AA Part B: Design Optimizes Dosing Paradigm and Assesses Treatment Durability
SIGNAL-AA Part B: Design Optimizes Dosing Paradigm and Assesses Treatment Durability Key Changes Treatment Period Off-Drug Period OLE Screening with Central Eligibility Review from Part A Bempikibart 200mg Efficacy & Safety Longer-term (n= 33) Follow-up Dosing Loading dose regimen Loading Regimen: C
Slide 5: Week 36 Data Demonstrate Robust Efficacy Across Different Disease Characteristics
Week 36 Data Demonstrate Robust Efficacy Across Different Disease Characteristics PK Loading regimen: Accelerated steady state levels (Week 3) with 3-fold higher mean trough (28.8 µg/mL) at Day 22 Efficacy at Week 36 35.3% 40.0% 30.3% mean SALT improvement from SALT≤20, mITT (10/25) SALT≤20, ITT (10
Slide 6: Bempikibart Was Well Tolerated with a Favorable Safety Profile
Bempikibart Was Well Tolerated with a Favorable Safety Profile 33 0 4% 36 Patients Enrolled Severe AEs Injection reactions Weeks on Treatment Part B, 52 weeks No life-threatening events Of total injections, all mild Through End of Treatment Key Safety Findings • No discontinuations due to safety eve
Slide 7: On-Target Biomarker Reductions Across IL-7 and TSLP Axes Supports Dual Mechanism
On-Target Biomarker Reductions Across IL-7 and TSLP Axes Supports Dual Mechanism CXCL10 Shift Tracks Clinical Response to Bempikibart On-target reductions in circulating biomarkers Responder biomarker downstream of IFN𝛄: CXCL10 Median % reduction from baseline Change from baseline at Week 36 IL-7…
Slide 8: Off-Treatment Efficacy Analysis: Assessing the Durability Potential of Bempikibart
Off-Treatment Efficacy Analysis: Assessing the Durability Potential of Bempikibart ▼ THIS ANALYSIS ▼ Treatment Period — 36 Weeks Off-Drug Follow-Up — 16 Weeks OLE Bempikibart 200 mg SC (4 weekly loading doses, then Q2W) No dosing; SALT assessed through Week 52 Long-term dosing Week 0 Week 36 Week 52
Slide 9: Off-Treatment Durability: Robust Efficacy Maintained Through 16 Week Off-drug Period
Off-Treatment Durability: Robust Efficacy Maintained Through 16 Week Off-drug Period ▼ THIS ANALYSIS ▼ Treatment Period — 36 Weeks Off-Drug Follow-Up — 16 Weeks OLE Bempikibart 200 mg SC (4 weekly loading doses, then Q2W) No dosing; SALT assessed through Week 52 Long-term dosing Week 0 Week 36 Week
Slide 10: Off-Treatment Durability: Week 36 Responders Maintained or Deepened Hair Growth
Off-Treatment Durability: Week 36 Responders Maintained or Deepened Hair Growth ▼ THIS ANALYSIS ▼ Treatment Period — 36 Weeks Off-Drug Follow-Up — 16 Weeks OLE Bempikibart 200 mg SC (4 weekly loading doses, then Q2W) No dosing; SALT assessed through Week 52 Long-term dosing Week 0 Week 36 Week 52 Po
Slide 11: Patient with Severe AA with Robust Response and Durability Off-Drug
Patient with Severe AA with Robust Response and Durability Off-Drug: SALT≤10 at Week 24 and 36, SALT-0 at Week 44; Maintained Off-Drug Treatment Period 16 Weeks Off-Drug • 48-year-old female; Duration of current episode: 1.2 years Baseline Week 36 Week 52 SALT≤10 at Week 36 which improved to SALT 0
Slide 12: Scalp Biopsy on Treatment: Marked Reduction in T-Cell Infiltrates in Hair Follicles
Scalp Biopsy on Treatment: Marked Reduction in T-Cell Infiltrates in Hair Follicles at Week 36, Concordant With Regrowth Clinical Background • 39 year old Female • Duration of current episode – 11 months Key Findings Baseline: • Lesional biopsy shows predominance of telogen/catagen hair follicles an
Slide 13: Bempikibart Signal AA Part B Summary
Bempikibart Signal AA Part B Summary • Responses in both severe and very severe disease, including JAKi-experienced patients • Favorable safety & tolerability • Response maintained or deepened across off-drug population • Biomarker reductions across IL-7 and TSLP axes • On-target CXCL10 reduction tr
Slide 14: Conclusions
Conclusions Novel biologic demonstrating robust safety and efficacy with potential for first-line use Biomarker data consistent with anticipated mechanism of IL7/TSLP targeting Maintenance dose predicted to be Monthly-Quarterly; currently being assessed in OLE Plans to initiate Phase 3 pivotal trial
Slide 15: Appendix Figures
Appendix Figures
Slide 16: Case Study: Initial Non-Responder Achieved SALT≤20 at 16 Weeks Following Final Dose
Case Study: Initial Non-Responder Achieved SALT≤20 at 16 Weeks Following Final Dose Treatment Period • 46-year-old female; Duration of current episode: 7 months 16 Weeks Off-Drug Baseline Week 36 Week 52 Early Signs of Hair regrowth at Week 36, with SALT≤20 response by Week 52, Patient enrolled into